Maricel Apuli Sells 510 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CAO Maricel Apuli sold 510 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $74.31, for a total value of $37,898.10. Following the completion of the sale, the chief accounting officer owned 123,945 shares of the company’s stock, valued at $9,210,352.95. The trade was a 0.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Maricel Apuli also recently made the following trade(s):

• On Monday, December 8th, Maricel Apuli sold 2,000 shares of BridgeBio Pharma stock. The stock was sold at an average price of $74.26, for a total transaction of $148,520.00.

BridgeBio Pharma Stock Down 4.3%

Shares of NASDAQ BBIO opened at $70.72 on Friday. The firm’s fifty day moving average is $75.66 and its 200 day moving average is $63.84. BridgeBio Pharma, Inc. has a 52 week low of $28.33 and a 52 week high of $84.94. The company has a market cap of $13.63 billion, a price-to-earnings ratio of -16.92 and a beta of 1.13.

Hedge Funds Weigh In On BridgeBio Pharma

A number of institutional investors have recently added to or reduced their stakes in the company. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in BridgeBio Pharma during the second quarter valued at $25,000. Aster Capital Management DIFC Ltd purchased a new position in BridgeBio Pharma during the 3rd quarter valued at about $31,000. Harvest Fund Management Co. Ltd bought a new stake in BridgeBio Pharma during the third quarter worth about $34,000. Jones Financial Companies Lllp purchased a new stake in BridgeBio Pharma in the first quarter worth about $35,000. Finally, First Horizon Corp bought a new position in shares of BridgeBio Pharma during the third quarter valued at approximately $36,000. Institutional investors own 99.85% of the company’s stock.

Wall Street Analyst Weigh In

BBIO has been the topic of a number of research analyst reports. Barclays initiated coverage on BridgeBio Pharma in a report on Wednesday, January 28th. They set an “overweight” rating on the stock. Sanford C. Bernstein started coverage on BridgeBio Pharma in a research note on Thursday, December 11th. They set an “outperform” rating and a $94.00 target price on the stock. Truist Financial upped their target price on BridgeBio Pharma from $80.00 to $86.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Wells Fargo & Company lifted their price target on shares of BridgeBio Pharma from $88.00 to $98.00 and gave the company an “overweight” rating in a report on Friday, February 13th. Finally, Morgan Stanley assumed coverage on shares of BridgeBio Pharma in a report on Tuesday, January 6th. They issued an “overweight” rating and a $96.00 price objective for the company. Twenty-two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $82.05.

BridgeBio Pharma News Summary

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Strong Phase 3 PROPEL 3 results in achondroplasia improve the drug candidate’s regulatory and commercial outlook — a clear catalyst lifting investor expectations and valuation. Read More.
• Positive Sentiment: HC Wainwright boosted EPS estimates across Q2–Q4/FY2026 and raised its price target to $100 while keeping a Buy rating, adding analyst conviction behind further upside. Read More.
• Positive Sentiment: Broad Wall Street support (multiple Buy/Overweight ratings and higher targets) provides additional demand if upcoming clinical/financials meet expectations. Read More.
• Neutral Sentiment: BridgeBio will report Q4 and full‑year 2025 results and host a Feb. 24 call — this scheduled event can cause short‑term volatility depending on revenue, cash burn and program updates. Read More.
• Neutral Sentiment: The company granted inducement RSUs (76,701 shares across 34 hires) — modest near‑term share‑based compensation to monitor for dilution. Read More.
• Neutral Sentiment: Oppenheimer added a small new 13F position (7,845 shares) — a modest institutional buy that signals some investor interest but is not yet material. Read More.
• Neutral Sentiment: Automated short‑interest reporting here shows inconsistent/zero figures (likely a reporting artifact); current short interest does not appear to be a material near‑term factor.
• Negative Sentiment: Clustered insider selling on Feb. 17: Director Randal Scott sold 10,000 shares (~$754k) and the CFO and CAO reported sales the same day — concentrated executive disposals can weigh on near‑term sentiment. Read More.
• Negative Sentiment: Ongoing pattern of executive selling highlighted in coverage — repeated insider liquidity events may keep downward pressure until insiders rebuild meaningful ownership. Read More.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.